Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia

NCT01670812 Phase 3 UNKNOWN

The purpose of this study is to investigate efficacy and safety of fresh frozen plasma(FFP), high dose methylprednisolone(HDMP) and rituximab for ultra-high risk chronic lymphocytic leukemia.

Details

Lead sponsor	The First Affiliated Hospital with Nanjing Medical University
Phase	Phase 3
Status	UNKNOWN
Enrolment	100
Start date	2012-01
Completion	2014-06

Conditions

• Chronic Lymphocytic Leukemia

Interventions

• FFP+HDMP+Rituximab

Primary outcomes

• overall response rate — one year
  overall response rate after treated by FFP+HDMP+Rituximab regimen

Countries

China